Section Arrow
Quote
LIPO.NASDAQ
- Lipella Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/05/31 22:01 EDT
Last
 0.6419
+0.0166 (+2.65%)
Day High 
0.662 
Prev. Close
0.6253 
1-M High
0.796 
Volume 
22.24K 
Bid
0.6419
Ask
0.68
Day Low
0.61 
Open
0.61 
1-M Low
0.6054 
Market Cap 
4.76M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 0.68 
20-SMA 0.71 
50-SMA 0.72 
52-W High 2.71 
52-W Low 0.6054 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/-0.28
Enterprise Value
4.80M
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
449.62K
Operating Revenue Per Share
0.02
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.5285-0.0308-5.51%-- 
SMMTSummit Therapeutics8.685-2.235-20.47%28.74PE
KTRAKintara Therapeutics0.3166-0.0004-0.13%-- 
SRPTSarepta Therapeutics129.86+5.41+4.35%289.42PE
NVAXNovavax15.03-0.22-1.44%-- 
Quotes are at least 15-min delayed：2024/05/31 22:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.